- Public Comps
- PharmaCielo
PharmaCielo Valuation Multiples
Discover PharmaCielo's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like SynBiotic, Humanoid Global Holdings, HYTN Innovations, Vitura Health and more.
PharmaCielo Overview
About PharmaCielo
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Founded
2017
HQ

Employees
260
Website
Financials (FY)
EV
$22M
Valuation Multiples
Start free trialPharmaCielo Financials
PharmaCielo reported last fiscal year revenue of $2M and negative EBITDA of ($316K).
In the same fiscal year, PharmaCielo generated $520K in gross profit, ($316K) in EBITDA losses, and had net loss of ($3M).
PharmaCielo P&L
In the most recent fiscal year, PharmaCielo reported revenue of $2M and EBITDA of ($316K).
PharmaCielo is unprofitable as of last fiscal year, with gross margin of 29%, EBITDA margin of (17%), and net margin of (141%).
Financial data powered by Morningstar, Inc.
PharmaCielo Stock Performance
PharmaCielo has current market cap of $9M, and enterprise value of $22M.
PharmaCielo's stock price is $0.04.
PharmaCielo has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $22M | $9M | 0.1% | - | - | - | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPharmaCielo Valuation Multiples
PharmaCielo trades at 11.9x EV/Revenue multiple, and (68.5x) EV/EBITDA.
PharmaCielo Financial Valuation Multiples
As of August 14, 2026, PharmaCielo has market cap of $9M and EV of $22M.
PharmaCielo has a P/E ratio of (3.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PharmaCielo Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


PharmaCielo Margins & Growth Rates
In the most recent fiscal year, PharmaCielo reported gross margin of 29%, EBITDA margin of (17%), and net margin of (141%).
PharmaCielo Margins
PharmaCielo Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
PharmaCielo Operational KPIs
PharmaCielo's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
PharmaCielo's Rule of 40 is (30%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PharmaCielo's Rule of X is (48%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
PharmaCielo Competitors
PharmaCielo competitors include SynBiotic, Humanoid Global Holdings, HYTN Innovations, Vitura Health, Avicanna, CordovaCann, Weed, Ubiquitech Software, Peak Processing and Strainsforpains.
Most PharmaCielo public comparables operate across Cannabis, CannaTech and ViceTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.7x | - | (5.1x) | - | |||
| 753.4x | - | (4.8x) | - | |||
| 8.9x | - | (13.0x) | - | |||
| 0.2x | - | 3.2x | - | |||
| 0.6x | - | (8.2x) | - | |||
| 0.8x | - | (13.1x) | - | |||
| - | - | (3.4x) | - | |||
| - | - | - | - | |||
This data is available for Pro users. Sign up to see all PharmaCielo competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by PharmaCielo
PharmaCielo has acquired 2 companies to date.
Last acquisition by PharmaCielo was on July 12th 2019. PharmaCielo acquired Melodiol Global Health for $79M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by PharmaCielo
| Description | - | - |
| HQ Country | ||
| HQ City | - | - |
| Deal Date | 12 Jul 2019 | 20 Apr 2018 |
| Valuation | $79M | $1M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all PharmaCielo acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PharmaCielo
| When was PharmaCielo founded? | PharmaCielo was founded in 2017. |
| Where is PharmaCielo headquartered? | PharmaCielo is headquartered in Canada. |
| How many employees does PharmaCielo have? | As of today, PharmaCielo has over 260 employees. |
| Is PharmaCielo publicly listed? | Yes, PharmaCielo is a public company listed on OTCM. |
| What is the stock symbol of PharmaCielo? | PharmaCielo trades under PCLOF ticker. |
| When did PharmaCielo go public? | PharmaCielo went public in 2018. |
| Who are competitors of PharmaCielo? | PharmaCielo main competitors include SynBiotic, Humanoid Global Holdings, HYTN Innovations, Vitura Health, Avicanna, CordovaCann, Weed, Ubiquitech Software, Peak Processing, Strainsforpains. |
| What is the current market cap of PharmaCielo? | PharmaCielo's current market cap is $9M. |
| What is the current revenue of PharmaCielo? | PharmaCielo's last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of PharmaCielo? | Current revenue multiple of PharmaCielo is 11.9x. |
| Is PharmaCielo profitable? | No, PharmaCielo is not profitable. |
| How many companies PharmaCielo has acquired to date? | As of August 2026, PharmaCielo has acquired 2 companies. |
| What was the largest acquisition by PharmaCielo? | $79M acquisition of Melodiol Global Health on 12th July 2019 was the largest M&A PharmaCielo has done to date. |
| What companies PharmaCielo acquired? | PharmaCielo acquired Melodiol Global Health and Ubiquo Telemedicine. |
| In how many companies PharmaCielo has invested to date? | PharmaCielo hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to PharmaCielo
Lists including PharmaCielo
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.






